Solid Tumor Targeting CAR-T Development Service through PNP Hydrogel

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service through PNP Hydrogel provides a comprehensive solution for overcoming the major barriers in solid tumor immunotherapy. Featuring enhanced tumor infiltration, minimized systemic toxicity, and dose-sparing advantages, this service leverages an injectable Polymer-Nanoparticle (PNP) hydrogel depot platform to locally deliver highly potent CAR-T cells. By integrating controlled release and sustained activity, it ensures profound anti-tumor efficacy while maintaining safety, offering researchers a rapid and effective approach to optimize their solid tumor CAR-T programs.

Why Choose PNP Hydrogel?

Standard systemic delivery is inefficient and often fails to provide sufficient cell numbers and activation at the tumor site, while high-dose cytokine support risks systemic toxicity. Creative Biolabs' solution addresses this unmet need by leveraging an injectable PNP hydrogel depot. This platform self-assembles in situ, establishing a local inflammatory niche that simultaneously promotes CAR-T expansion and provides prolonged, controlled release of stimulatory cytokines, thereby profoundly improving anti-tumor efficacy and consistency of treatment.

Creative Biolabs' Service

Creative Biolabs' advanced PNP Hydrogel platform overcomes the critical biological and physical barriers that hinder systemic CAR-T delivery in solid tumors. We provide a comprehensive solution for locoregional delivery that simultaneously supports CAR-T cell health and controls the local immune microenvironment. Our service delivers a transient, yet potent, inflammatory niche to maximize therapeutic cell persistence and activity directly at the tumor site, or for metastatic applications. This technology is critical for projects aiming to:

• Enhance CAR-T Cell Expansion and Persistence: Create a localized reservoir that promotes up to a 100-fold increase in T cell expansion compared to standard IV controls.
• Reduce Systemic Toxicity: Achieve sustained exposure to stimulatory cytokines directly at the site of action while significantly reducing the toxic maximum serum concentration associated with systemic administration.
• Induce a Tumor-Reactive Phenotype: Facilitate the development and maintenance of desirable T cell memory subsets.

Discover How We Can Help - Request a Consultation.

Key Technical Elements

Our Workflow

Creative Biolabs offers a streamlined, professional, and optimized workflow designed for rapid and reproducible results, culminating in a robust CAR-T delivery system ready for preclinical testing.

The final deliverables include a PNP hydrogel formulation protocol, pharmacokinetic and release data, and a preclinical efficacy report detailing tumor clearance and T cell expansion.

Core Benefits

• Integrated Biomaterials Development: A one-stop service covering polymer synthesis, nanoparticle functionalization, and final hydrogel component manufacturing at scales suitable for advanced preclinical studies.
• Encapsulation Optimization: Rigorous process development to maximize the viability and function of the encapsulated CAR-T cells, ensuring minimal cell damage during the high-shear injection process.
• Aseptic and Traceable Manufacturing: Strict aseptic procedures throughout the CAR-T cell handling and hydrogel formulation steps, providing full documentation of component origin and quality assurance for translational studies.

Published Data

This study addresses the poor efficacy of adoptive cell therapy in solid tumors by developing an injectable hydrogel for localized delivery. This biomaterial co-delivers CAR-T cells and cytokines, creating a supportive "inflammatory niche" that enhances cell retention and activation. Its unique structure allows entrapped cells to actively migrate while preventing cytokine diffusion.

Fig.1 PNP hydrogel for the codelivery of CAR-T cells and cytokines to improve solid tumor therapy.¹

FAQs

Partner with Us

Creative Biolabs is your expert partner in overcoming the final hurdle for solid tumor CAR-T therapy. Our Solid Tumor Targeting CAR-T Development Service through PNP Hydrogel delivers a validated, injectable platform that enhances T cell expansion, improves tumor-reactive phenotype, and dramatically reduces systemic toxicity risks. To learn how Creative Biolabs can customize this cutting-edge platform for your specific solid tumor target and accelerate your timeline, please reach out to our specialist team today.

Reference

1. Huang, Guojun, et al. "Bioactive-Material-Programmed CAR-T Cell Living Drug for Augmented Immunotherapy against Tumors." Cell Reports Physical Science, 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1016/j.xcrp.2024.102022